arzerra
glaxosmithkline argentina s.a. - ofatumumab - solucion p/infusion - ofatumumab 20 mg/ml
tysabri 300mg/15ml concentrado para solucion para perfusion
stendhal peru s.a. - droguerÍa - natalizumab - concentrado para solucion para perfusion - 300mg/15ml - por mililitro 20.00 mg - - natalizumab
mitoxantrona accord 2 mg/ml concentrado para solucion para perfusion efg
accord healthcare s.l.u. - mitoxantrona hidrocloruro - concentrado para soluciÓn para perfusiÓn - 2 mg/ml inyectable 10 ml - mitoxantrona hidrocloruro 2 mg - mitoxantrona
mitoxantrona sandoz 2 mg/ml concentrado para solucion para perfusion
sandoz farmaceutica s.a. - mitoxantrona hidrocloruro - concentrado para soluciÓn para perfusiÓn - 2 mg/ml inyectable 10 ml - mitoxantrona hidrocloruro 2 mg - mitoxantrona
novantrone 2 mg/ml concentrado para solucion para perfusion
mylan ire healthcare limited - mitoxantrona - concentrado para soluciÓn para perfusiÓn - 2 mg/ml inyectable 10 ml - mitoxantrona 2 mg - mitoxantrona
gilenya 0.5 mg capsula dura
novartis biosciences peru s.a. - droguerÍa - clorhidrato de fingolimod; - capsula dura - por capsula - - fingolimod
tysabri
biogen netherlands b.v. - natalizumab - esclerosis múltiple - inmunosupresores selectivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
mitoxantrona 20mg/10ml concentrado para solucion para perfusion
medifarma s.a. - concentrado para solucion para perfusion - por vial - mitoxantrona
mitoxantrona 20mg/10ml concentrado para solucion para perfusion
global med farma s.a.c. - droguerÍa - concentrado para solucion para perfusion - por mililitro - - mitoxantrona
zeposia
bristol-myers squibb pharma eeig - ozanimod clorhidrato de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - inmunosupresores - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.